1. Added value of diabetes risk genes to the prediction of HbA1c levels in patients initiating metformine or sulfonylurea derivatives.: German Pharm-Tox Summit, Göttingen

   Martono, D., Heerspink, H., Hak, E., Denig, P. & Wilffert, B. Feb-2018 In : Naunyn-Schmiedebergs Archives of Pharmacology. 391, Supplement 1, p. S15 1 p., 55

   Research output: Contribution to journal › Meeting Abstract

2. Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study

   Apperloo, E. M., Pena, M. J., de Zeeuw, D., Denig, P. & Heerspink, H. 18-Jan-2018 In : Diabetes obesity & metabolism.

   Research output: Contribution to journal › Article

3. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

   Gant, C. M., Laverman, G. D., Vogt, L., Slagman, M. C. J., Heerspink, H. J. L., Waanders, F., Hemmelder, M. H., Navis, G. & Holland Nephrology Study (HONEST) Network 20-Dec-2017 In : Bmc nephrology. 18, 8 p., 370

   Research output: Contribution to journal › Article

4. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension

   Lindhardt, M., Persson, F., Oxlund, C., Jacobsen, I. A., Zürbig, P., Mischak, H., Rossing, P. & Heerspink, H. J. L. Feb-2018 In : Nephrology, Dialysis, Transplantation. 33, 2, p. 296-303 8 p.

   Research output: Contribution to journal › Article

5. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

   Petrykiv, S., Laverman, G. D., de Zeeuw, D. & Heerspink, H. J. L. Jan-2018 In : Diabetes obesity & metabolism. 20, 1, p. 224-227 4 p.

   Research output: Contribution to journal › Article

View all (203) »